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Abstract
Aims/hypothesis This long-term study was designed to
further characterise the retinal safety profile of insulin
glargine and human neutral protamine Hagedorn (NPH)
insulin in patients with type 2 diabetes mellitus.
Methods An open-label, 5 year, randomised (1:1), multi-
centre, stratified, parallel-group study conducted in the
USA and Canada enrolled individuals with type 2 diabetes
and either no or non-proliferative retinopathy (less than
severe; Early Treatment Diabetic Retinopathy Study
[ETDRS] level less than 53 in both eyes) who were treated
with oral hypoglycaemic agents (OHAs) alone, insulin
alone or OHAs with insulin for ≥3 months prior to study
entry and a baseline HbA1c level of 6.0–12.0%. Patients
were randomised by the investigator according to the
centralised interactive voice response system to receive
twice-daily NPH insulin (n=509) or once-daily basal
insulin glargine (n=515). The investigator was not blinded
to the treatment group to which each participant had been
assigned. The main objective of this study was to compare
the progression of diabetic retinopathy between treatment
groups by analysing the percentage of patients with three or
more step progression in the ETDRS retinopathy patient-
level severity scale after treatment with either basal insulin.
Masked, centralised grading of seven-field stereoscopic
fundus photographs was used.
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Madison, WI, USAResults Similarly sustained glycaemic control was observed
in both the insulin glargine and NPH insulin treatment
groups. Despite a slightly greater severity of diabetic
retinopathy for the insulin glargine group at baseline, three
or more step progression in ETDRS score from baseline to
end-of-study was similar between treatment groups (14.2%
[53/374] of insulin glargine-treated patients vs 15.7% [57/
363] of NPH-treated patients); the difference in the
incidence of progression was −1.98% (95% CI −7.02,
3.06%). Other measures of retinopathy—the development
of proliferative diabetic retinopathy and progression to
clinically significant macular oedema—occurred to a
similar degree in both treatment groups. No other safety
issues, such as unexpected adverse events for either insulin
emerged during the 5 year study. However, NPH insulin
treatment was associated with a higher incidence of severe
hypoglycaemia compared with insulin glargine.
Conclusions/interpretation This study shows no evidence
of a greater risk of the development or progression of
diabetic retinopathy with insulin glargine vs NPH insulin
treatment in patients with type 2 diabetes mellitus.
Trial registration ClinicalTrials.gov NCT00174824
Funding This study was sponsored by sanofi-aventis.
Keywords CSME.ETDRS.Insulinaction.
Insulin glargine.Insulintherapy.NPHinsulin.
Retinopathy.Type2diabetes
Abbreviations
ETDRS Early Treatment Diabetic Retinopathy Study
FPG Fasting plasma glucose
ITT Intention-to-treat
LS Least square
NPH Neutral protamine Hagedorn
OHA Oral hypoglycaemic agent
PP Per protocol
UKPDS UK Prospective Diabetes Study
Introduction
Clinical trials in patients with type 1 and type 2 diabetes
mellitus have established that maintenance of near-
normoglycaemic control reduces the risk of microvascular
complications, such as diabetic retinopathy [1–5]. To
facilitate reaching glycaemic goals without excessive
hypoglycaemia, analogues of human insulin with improved
pharmacokinetic and pharmacodynamic action profiles
have been developed [6–9].
Insulin glargine (A21Gly,B31Arg,B32Arg human insu-
lin) is a recombinant, long-acting basal insulin analogue
that differs from human insulin by the substitution of
glycine for asparagine at position 21 of the A chain and the
addition of two arginines at the C-terminus of the B chain.
These changes produce an insulin with a duration of action
of approximately 24 h or more after subcutaneous injection,
without pronounced peaks of activity [10]. In clinical trials,
a single daily injection of insulin glargine provides
glycaemic control equivalent to that afforded by neutral
protamine Hagedorn (NPH) insulin [11–15], but with a
lower risk of hypoglycaemia [16, 17].
One of the five 6 month, phase 3 registration trials of
insulin glargine [14] reported that the percentage of par-
ticipants with an increase of three or more steps on the Early
Treatment Diabetic Retinopathy Study (ETDRS) retinopathy
severity scale was greater in the insulin glargine group
(7.0%) than in the human NPH insulin group (2.7%). This
finding may have been related to chance or to differences at
baseline in the patients studied, especially since no retinop-
athy entrance criteria were specified and the data showed
more of a ‘scatter’ and did not follow a natural progression
[18]. However, because of the potential importance of this
finding, a carefully designed clinical trial of sufficient
duration and statistical power was conducted to address the
long-term safety of insulin glargine compared with human
NPH insulin. Here we report the findings of this trial, which
used change on the ETDRS scale based on the masked,
centralised grading of seven-field stereoscopic fundus
photographs as the primary measure of retinopathy pro-
gression in patients with type 2 diabetes mellitus [19].
Methods
Study design This was a 5 year, multicentre, multinational
(USA and Canada), randomised (1:1), open-label, human
NPH insulin-controlled, parallel-group study in patients
with type 2 diabetes mellitus suited to treatment with a basal
insulin. The study recruited male or female type 2 diabetes
mellitus patients, aged 30–70 years, with a diagnosis of type
2 diabetes mellitus for ≥1 year, treated with oral hypogly-
caemic agents (OHAs), or insulin alone or in combination,
for ≥1 year prior to screening, with a stable dose(s) for
≥3 months prior to screening. HbA1c was required to be
6.0–12.0% at screening. Exclusion criteria included the
presence of proliferative or severe non-proliferative diabetic
retinopathy (ETDRS level 53 or greater in either eye); laser
photocoagulation or vitrectomy prior to study entry; use of
any insulin analogues ≤3 months prior to screening; systolic
blood pressure >150 mmHg or diastolic blood pressure
>95 mmHg at screening; and a history of hypoglycaemia
unawareness (more than two severe hypoglycaemia epi-
sodes without warning in the past year). The study was
conducted in accordance with the Declaration of Helsinki,
and approval by institutional ethics committees was
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written informed consent prior to study entry.
Study treatment Before randomisation, eligible patients
were stratified on a 1:1 basis by baseline HbA1c level
(6.0–9.0% and >9.0–12.0%) to ensure that the patients in
each HbA1c category were distributed equally between the
two treatment groups. Following randomisation, patients
received open-label insulin glargine once daily, generally at
bedtime, or NPH insulin twice daily, generally in the
morning and at bedtime.
In both groups, insulin doses were titrated over the first
3 years of the study, with the aim of achieving fasting
plasma glucose (FPG) levels of ≤6.7 mmol/l (≤120 mg/dl).
This target was reduced to ≤5.5 mmol/l (≤100 mg/dl) for
the last 2 years of the study. Whilst attempting to reach
these glycaemic goals, OHAs and/or prandial insulin doses
taken at baseline could be continued or modified during the
trial, and human regular insulin could be added with meals
even if not used at baseline, at the investigator's discretion.
However, no specific titration guidelines for pre-meal
regular insulin dosing were provided.
Outcome and safety measures The primary objective of this
study was to compare the percentage of patients with three or
more step progression in ETDRS score after 5 years of
treatment with either insulin glargine or NPH insulin. The
secondary efficacy assessments included the percentage of
patients with three or more step progression in ETDRS score
after 3, 6, 12, 24, 36, 48 and 60 months of treatment; the
percentage of patients who developed proliferative diabetic
retinopathy; the distribution of change on the ETDRS scale; the
percentage of patients who developed clinically significant
macular oedema; the change from baseline in overall HbA1c
and FPG levels; the overall incidence and rate of symptomatic
hypoglycaemia (all episodes of symptomatic hypoglycaemia),
symptomatic nocturnal hypoglycaemia and severe hypogly-
caemia (symptomatic hypoglycaemia requiring assistance and
either with blood glucose levels of ≤3.1 mmol/l or treated with
oral or injectable carbohydrate or glucagon injection); and
insulin doses. Weight, blood pressure (recorded in the seated
position), HbA1c (performed by the Diabetes Diagnostic
Laboratories, Columbia, MO, USA, using the National
Glycohemoglobin Standardization Programme [level 1]) [5]
and FPG (performed locally for each site by laboratories that
were required to be Clinical Laboratory Improvement
Amendment-certified) were measured every 3 months.
Patients were provided the Accu-Chek blood glucose meter
(Roche Diagnostics, Indianapolis, IN, USA) and instructed on
how to use it during the screening phase; they were asked to
measure blood glucose at least twice a day.
Diabetic retinopathy status was assessed in seven-field
stereoscopic fundus photographs obtained at screening and
after 3, 6, 12, 24, 36, 48 and 60 months of treatment [19–21].
Photographs underwent treatment-group-masked grading,
without comparison with other photographs, at the Univer-
sity of Wisconsin Fundus Photograph Reading Centre
(FPRC). To verify progression status, a side-by-side com-
parison of baseline and follow-up photographs masked to
treatment was conducted by a senior grader for any patient
whose ETDRS score demonstrated a three step or greater
progression over baseline at any time point during the study.
Safety was assessed by the evaluation of reported
adverse events using the Medical Dictionary for Regula-
tory Activities (MedDRA) coding (Version 10.0; MSSO,
Chantilly, VA, USA). Additional safety assessments were
severe hypoglycaemia; physical examinations, including
periodic funduscopic examinations; vital signs (seated)
and body weight; laboratory serum creatinine and lipo-
protein levels were performed by Covance Central
Laboratory Services (Covance CLS, Indianapolis, IN,
USA) using the Roche Modular Analyzer (Roche Diag-
nostics, Manheim, Germany).
Statistical methods Sample size was calculated assuming a
20% 5 year event rate for a three or more step progression
in diabetic retinopathy on the ETDRS scale from baseline
to end of study (based on data from the DCCT [22]), and a
non-inferiority margin of 10% (half of the expected
background rate of 20%) was chosen. Assuming that
approximately 40% of the randomised patients would not
be evaluable, a sample size of 840 randomised patients (420
per treatment group) was calculated to provide at least 80%
power for declaring non-inferiority.
The per protocol (PP) population consisted of patients who
had undergone at least 4 years of treatment (not necessarily
consecutively) with the study drug and who had evaluable
fundusphotographs takenatleast 4.5years after startingstudy
medication, or who had three or more step progression of
retinopathy on the ETDRS scale. The PP population was the
primary analysis population for the primary outcome end-
point. An intention-to-treat (ITT) population (all randomised
patients who received at least one dose of study medication)
was used to confirm the PP primary analyses and was the
populationusedforallsecondaryanalyses.However,asmany
clinical trials use the ITT population for the primary analysis,
in this paper we initially present the ITT population results
followed by the PP population analysis.
The primary efficacy analysis was conducted using a
generalised linear model (generated by the statistics
software SAS GENMOD, Version 8 [SAS, Cary, NC,
USA]) with the response of three step or greater progres-
sion in the ETDRS from baseline to endpoint as the
dependent variable, treatment and baseline HbA1c strata as
the classified independent variables, and with binomial
distribution and identity link function. The 95% CIs were
1780 Diabetologia (2009) 52:1778–1788derived from least square (LS) mean results. A stepwise
closed testing approach was used for the primary efficacy
analysis. First, non-inferiority was demonstrated if the
upper bound of the 95% CI for the treatment difference in
the participants with a three step or greater progression in
the ETDRS from baseline to endpoint between insulin
glargine and NPH insulin in the PP population was ≤10%.
Second, non-inferiority and superiority (upper bound of
95% CI <0.0%) were tested in the ITT population. The
overall α level for significance was 0.05.
Results
Patient demographics and baseline characteristics Figure 1
shows the disposition of study participants. Patients in the
two treatment groups were generally similar in terms of
baseline characteristics (Table 1). The majority of partic-
ipants had previously been treated with OHAs, and 69%
had been treated with insulin for an average of 5 years
prior to study entry. The mean duration of prior insulin
use, percentage of participants with a history of diabetic
retinopathy, and the percentage of participants with
diabetic retinopathy of moderate non-proliferative sever-
ity or worse (ETDRS level 43 or greater in either eye) by
photograph grading were all slightly greater at baseline
for the insulin glargine group than for the NPH insulin
group. More participants in the insulin glargine group
than in the NPH insulin group had Grade C macular
oedema at baseline. Mean systolic and diastolic blood
pressures were comparable in the two treatment groups;
60.4% and 60.9% of patients randomised to the insulin
glargine and NPH insulin groups, respectively, had
hypertension at baseline.
Total
randomised
n=1,024
Total randomised to
insulin glargine
n=515
Premature withdrawal
n=139
• Participant no longer met criteria 
to remain in study (7)
• New adverse event or worsening 
of an existing adverse event (17)
• Lack of efficacy (4)
• Poor compliance (6)
• Participant did not wish to 
continue (40)
• Participant lost to follow-up (28)
• Administrative reasons (5)
• Protocol violation (1)
• Participant died (11)
• Investigator’s discretion (7)
• Hypoglycaemia (1)
• Other reason (12)
ITT population
n=513
Total completed
n=374
PP population
n=374
Safety populationa
n=514
Randomised but not treated
n=2
• Participant did not wish to
continue (2)
Total randomised to
NPH insulin
n=509
ITT populationa a
n=504
Total completed
n=364
PP population
n=363
Safety populationa
n=503
Premature withdrawal
n=140
• Participant no longer met criteria 
to remain in study (2)
• New adverse event or worsening 
of an existing adverse event (12)
• Lack of efficacy (2)
• Poor compliance (7)
• Participant did not wish to 
continue (51)
• Participant lost to follow-up (35)
• Administrative reasons (4)
• Participant died (11)
• Investigator’s discretion (6)
• Hypoglycaemia (1)
• Other reason (9)
Randomised but not treated
n=5
• Investigator’s discretion (1)
• Participant did not wish to
continue (3)
• Participant no longer met
criteria to remain in study (1)
Fig. 1 Summary of participant randomisation and disposition. This
study was conducted between June 2001 and April 2007. Patients
entering the screening phase (1,413 participants were screened at 46
sites in the USA and 16 sites in Canada) received a participant number
and, following fulfilment of inclusion criteria (at the end of the
screening phase), were randomised by the investigator according to
the centralised interactive voice response system (IVRS). The
randomisation schedule (1:1) was stratified by investigational centre
and baseline HbA1c levels (6.0–9.0% and >9.0–12.0%). The investi-
gator was not blinded to the treatment group to which each participant
had been assigned.
aOne patient who was randomised to receive NPH
insulin received insulin glargine throughout the study, and is
consequently counted in the ITT population as an NPH patient, but
in the safety population as an insulin glargine patient, leading to a
discrepancy in the numbers for the ITT and safety populations in both
the insulin glargine and NPH insulin arms
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shows the metabolic changes over time in the two treatment
arms. Overall, FPG declined in both treatment groups early
in the study, and then reached a plateau until endpoint
(Fig. 2a). In the insulin glargine group, this decline was
from a mean baseline level of 10.6±3.7 mmol/l to a mean
endpoint level of 7.8±3.2 mmol/l; in the NPH insulin
group, FPG decreased from a mean of 10.0±3.4 mmol/l to
Variable Insulin glargine (n=513) NPH insulin (n=504)
Age, years 54.9±8.8 55.3±8.5
Age category, n (%)
<65 years 429 (83.6) 427 (84.7)
65–75 years 84 (16.4) 77 (15.3)
Sex, n (%)
Male 278 (54.2) 270 (53.6)
Female 235 (45.8) 234 (46.4)
Weight, kg 100.2±22.7 98.7±22.3
Height, cm 170.1±10.1 170.1±10.3
BMI, kg/m
2 34.5±7.2 34.1±7.2
Duration of diabetes, years 10.7±6.9 10.8±6.7
HbA1c, % 8.41±1.38 8.31±1.38
FPG, mmol/l 10.5±3.7 10.0±3.4
Previous glucose-lowering treatment, n (%) 513 (100) 504 (100)
Prior treatment with OHA, n 494 476
Duration, years 9.0±6.3 8.9±5.7
Prior treatment with insulin, n 344 354
Duration, years 5.5±6.0 4.9±5.1
Diabetic late complications, n (%)
Total 308 (60.0) 291 (57.7)
Diabetic retinopathy 80 (15.6) 61 (12.1)
Diabetic nephropathy 60 (11.7) 48 (9.5)
Diabetic neuropathy 245 (47.8) 241 (47.8)
Diabetic macroangiopathy 64 (12.5) 67 (13.3)
Blood pressure, n 514 503
Systolic blood pressure, mmHg 131.5±14.9 130.5±13.8
Diastolic blood pressure, mmHg 77.3±9.1 76.9±9.0
Baseline ETDRS retinopathy severity, n (%)
No DR 198 (38.6) 196 (38.9)
Microaneurysms only, one eye
a 73 (14.2) 83 (16.5)
Microaneurysms only, both eyes
a 43 (8.4) 44 (8.7)
Mild NPDR (level 35/<35 or 35/35) 146 (28.5) 142 (28.2)
Moderate NPDR or worse (level 43/<43 or worse) 53 (10.3) 39 (7.7)
Modified CSMO score
b, n (%) 374 363
Right eye
Level A 352 (94.1) 352 (97.0)
Level B 12 (3.2) 7 (1.9)
Level C 7 (1.9) 1 (0.3)
Level D 3 (0.8) 2 (0.6)
Left eye
Level A 355 (94.9) 347 (95.6)
Level B 7 (1.9) 12 (3.3)
Level C 10 (2.7) 0
Level D 2 (0.5) 3 (0.8)
Missing 0 1 (0.3)
Table 1 Patient demographics
and baseline characteristics
Data are mean±SD unless
otherwise stated; all values refer
to the ITT population unless
otherwise stated
aEyes without microaneurysms
but with retinal haemorrhages or
exudates were included here
bPP population, consisting of
374 participants in the insulin
glargine group; 363 participants
in the NPH insulin group.
Level A, no macular oedema;
Level B, macular oedema
present but not clinically
significant; Level C, CSMO but
centre of macula not involved;
Level D, CSMO with centre of
macula involved
DR, diabetic retinopathy;
NPDR, non-proliferative
diabetic retinopathy; CSMO,
clinically significant macular
oedema
1782 Diabetologia (2009) 52:1778–1788a mean of 7.7±3.2 mmol/l (ITT population). Insulin
glargine treatment increased the percentage of patients
achieving the target FPG (≤5.6 mmol/l) from 6.4% at
baseline to 28.5% at endpoint; NPH insulin treatment
caused an increase from 7.7% to 24.3%.
Mean HbA1c in the ITT population declined in both
groups during the first 6 months of the study and remained
similarly stable thereafter (Fig. 2b). At study end, mean
HbA1c (last observation carried forward) improved from a
baseline of 8.4% and 8.3% to 7.8% and 7.6% for all
patients in the insulin glargine and NPH insulin groups,
respectively (Table 2). The mean HbA1c change from
baseline was −0.55% with insulin glargine and −0.76%
with NPH insulin (LS mean difference 0.21 more with NPH
insulin, 95% CI 0.06–0.35; p=0.0053). An exploratory post
hoc analysis of the subgroup of patients who were taking
basal insulin with OHAs, but no regular insulin, which
included 168 and 155 insulin glargine-treated and NPH
insulin-treated patients, respectively, showed that mean
HbA1c values were equivalent between treatment groups
throughout the study (Fig. 2c).
The mean basal insulin dose at endpoint was lower for
insulin glargine than for NPH insulin (62±39 and 72±48 IU,
respectively; Table 2). The daily dose of prandial insulin
administered at the end of the study was 44±42 and
32±38 IU for insulin glargine and NPH insulin, respec-
tively, for the subset of patients taking prandial insulin. The
mean daily total insulin doses (basal plus prandial insulin)
by the endpoint of the study were 89±66 IU for the insulin
glargine group and 92±66 IU for the NPH insulin group.
Frequencies of the three defined categories of hypogly-
caemia in this study are shown in Table 2. NPH insulin
treatment was associated with a greater incidence of severe
hypoglycaemia than was insulin glargine (11.1% [55/494]
vs 7.6% [38/501], respectively; p=0.0439). Analysis of the
yearly rate rather than the patient incidence revealed that
there was a significant difference between the two groups
with respect to symptomatic hypoglycaemia (mean yearly
rate of 7.08±16.49 with NPH insulin vs 5.13±12.79 with
insulin glargine; p=0.0017; Table 2; Fig. 2d).
Retinopathy progression The ITT analysis showed a differ-
ence of −2.10% (95% CI −6.29%, 2.09%) between the two
treatment arms in the proportion of patients with three or
more step progression (ETDRS scale), the proportion being
lower for insulin glargine (Table 3). As the upper bound of
the 95% CI was >0 in the ITT analysis, superiority of
Fig. 2 Metabolic changes (mean±SD) during the course of the study
from baseline to endpoint (last observation carried forward) in the
insulin glargine and NPH insulin groups. a Change in FPG levels over
time with twice-daily NPH insulin (squares) and once-daily insulin
glargine (triangles; ITT population). b Change in HbA1c levels over
time with twice-daily NPH insulin (squares) and once-daily insulin
glargine (triangles; ITT population). c Change in HbA1c levels over
time with twice-daily NPH insulin (squares) and once-daily insulin
glargine (triangles) in patients treated with basal insulin plus OHAs
only (ITT population). d Summary of patient mean yearly rate of
hypoglycaemia with twice-daily NPH insulin (black bars) and once-
daily insulin glargine (white bars) (ITT population). Yearly rate of
hypoglycaemia was calculated by 365.25×(number of episodes in the
period)/(number of days in period)
b
Diabetologia (2009) 52:1778–1788 1783Table 2 Summary of the metabolic efficacy results (ITT population)
Variable Insulin glargine
(n=513)
NPH insulin
(n=504)
Difference between
groups, LS mean±SEM
95% CI p value
HbA1c at endpoint (%) 7.80±1.33 7.56±1.31
Change from baseline −0.55±0.06 −0.76±0.06 0.21±0.07 0.06, 0.35 0.0053
FPG at endpoint (mmol/l) 7.8±3.2 7.7±3.2
Change from baseline −2.5±0.2 −2.5±0.2 −0.04±0.2 −0.4, 0.4 0.8414
Weight at endpoint (kg) 103.2±24.5 103.0±23.7
Change from baseline 3.7±0.46 4.8±0.46 −1.2±0.60 −2.34, 0.00 0.0505
Basal daily insulin dose
at endpoint (IU)
61.84±39.41 72.31±47.52
Prandial daily insulin dose
at endpoint (IU)
43.83±41.62 31.81±37.68
Daily insulin dose at endpoint
(basal plus prandial) (IU)
88.59±65.92 91.80±66.36 −3.16±4.12 −11.24, 4.93 0.4438
Patients with hypoglycaemic events
a
Symptomatic hypoglycaemia 370 (73.9) 385 (77.9) 0.1366
Symptomatic nocturnal hypoglycaemia 281 (56.1) 296 (59.9) 0.2248
Severe hypoglycaemia 38 (7.6) 55 (11.1) 0.0439
Patients' mean yearly rate of hypoglycaemia
a
Symptomatic hypoglycaemia 5.13±12.79 7.08±16.49 0.0017
Symptomatic nocturnal hypoglycaemia 1.66±4.25 2.11±4.88 0.0705
Severe hypoglycaemia 0.04±0.23 0.06±0.30 0.0563
Data are mean±SD or n (%) unless otherwise stated. The 95% CIs were calculated for the LS mean difference
aFrom month 3 to endpoint. Number of participants included in analysis: 501 and 494 in the insulin glargine and NPH insulin groups, respectively
Table 3 Summary of the retinal efficacy results (ITT and PP populations)
Subgroup n/N
a (%) Difference between groups, LS mean±SEM 95% CI p value
Insulin glargine NPH insulin
Patients with ≥3 step progression in ETDRS score at endpoint
ITT 63/502 (12.5) 71/487 (14.6) −2.10±2.14 −6.29, 2.09 –
b
PP 53/374 (14.2) 57/363 (15.7) −1.98±2.57 −7.02, 3.06 –
b
Patients developing PDR during the study
ITT 25/496 (5.0) 16/483 (3.3) –– 0.2095
PP 20/373 (5.4) 14/363 (3.9) –– 0.5064
Patients developing CSMO
c during the study
ITT 68/493 (13.8) 68/481 (14.1) –– 0.8818
PP 58/371 (15.6) 53/362 (14.6) –– 0.7674
Results are n (%) unless otherwise stated, as appropriate for the ITT or PP populations. The 95% CIs were calculated for the LS mean difference
an/N, number/total number analysed
bConfidence intervals rather than p values were used to assess the primary outcome in this non-inferiority trial
cAny eye was considered to have developed clinically significant macular oedema (CSMO) if the eye's modified CSMO score increased to level C
or D from level A or B at baseline, at any time during the trial, or if an eye at level A or B at baseline had undergone focal/grid photocoagulation
at any time during the trial. For a description of the different CSMO levels, see the footnotes to Table 1. An eye was excluded from the analysis if
it had previous focal/grid photocoagulation at baseline. A patient was considered to have developed CSMO if either or both eyes had developed
CSMO
PDR, proliferative diabetic retinopathy
1784 Diabetologia (2009) 52:1778–1788insulin glargine over NPH insulin was not demonstrated. At
endpoint in approximately 14% of patients in each
treatment group, retinopathy had progressed by three or
more steps. There were no differences between treatments
in the proportion of patients with three or more step
progression in ETDRS score at endpoint in either of the two
randomised HbA1c strata (6.0–9.0% and >9.0–12.0%).
The primary analysis population for retinopathy progres-
sion was, however, the PP population, and Fig. 3 shows the
incidence of progression of retinopathy compared with
baseline at various stages of treatment in these patients. At
the end of 1 year of treatment, three or more step
progression in ETDRS score was observed in 4.6% and
5.8% of insulin glargine-treated and NPH insulin-treated
participants, respectively (Fig. 3a). The frequency of
patients showing three or more step ETDRS progression
continued to increase in year 2 (8.1% vs 9.4% in the insulin
glargine and NPH insulin groups); Fig. 3a presents the
incidence of progression over time for both treatment
groups. At endpoint, 14.2% (53/374) of insulin glargine-
treated patients and 15.7% (57/363) of NPH insulin-treated
patients in the PP population had three or more step
progression in ETDRS score (Fig. 3b). The difference in the
incidence of progression was −1.98% (95% CI −7.02%,
3.06%) for insulin glargine vs NPH insulin, demonstrating
non-inferiority of insulin glargine compared with NPH
insulin. At endpoint, in approximately 25% of patients in
each treatment group, retinopathy had progressed by two or
more steps (ESM Fig. 1).
On analysis of the development of ophthalmic lesions,
neither the proliferative diabetic retinopathy development
rate nor the incidence of progression to clinically significant
macular oedema were significantly different between
treatment groups over 5 years in either the ITT or PP
populations (Table 3).
Safety profile Body weight gain tended to be greater with
NPH insulin than with insulin glargine, with a baseline to
endpoint increase in mean body weight of 3.7 kg for insulin
glargine and 4.8 kg for NPH insulin (ITT population; p=
0.0505; ESM Fig. 2).
The rates of adverse events were similar for the two
treatments (ESM Table 1). As shown in ESM Table 2,
disparities between treatment groups for events with an
incidence of at least 5% in the insulin glargine group, with
a difference in incidence by treatment group of at least 1%,
were not remarkable in any case. There was no observable
trend for a difference in the incidence of serious adverse
events, as well as adverse events leading to study
withdrawal, and the overall incidence of adverse events
leading to death was low and comparable between
treatment groups (ESM Table 1).
There were minimal changes in mean blood pressure in
both treatment groups from baseline to endpoint in the ITT
population. For the insulin glargine and NPH insulin
groups, LS mean change from baseline to endpoint systolic
blood pressure was +1.1±0.8 and +1.6±0.8 mmHg and
diastolic blood pressure was −2.4±0.4 and −2.2±0.4 mmHg,
respectively.
Discussion
This study was specifically designed to detect differences in
the incidence of retinopathy progression by fundus photog-
raphy over a 5 year period. To ensure the greatest possible
objectivity of this assessment, retinopathy scoring was
conducted at a single ophthalmologic centre, in a stand-
ardised fashion, by specially trained and certified graders
who were masked to treatment. Throughout the study,
changes in ETDRS scores in each group were remarkably
similar, with no significant differences between treatment
Fig. 3 Primary and secondary retinopathy outcomes following
treatment with either twice-daily NPH insulin (black bars) or once-
daily insulin glargine (white bars; PP population). a Prevalence of
three or more step progression on the ETDRS retinopathy severity
scale during the course of the study. Percentage of patients calculated
using the number of PP population as denominator. b Proportion of
patients with three or more step progression on the ETDRS scale at
endpoint. Percentage of patients calculated using the number of
participants in the PP population as the denominator. There were 57/
363 (15.7%) of NPH insulin-treated patients and 53/374 (14.2%) of
insulin glargine-treated patients with three or more step progression on
the ETDRS. The difference in progression rate between treatment
groups was −1.98 (95% CI −7.02, 3.06)
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the number of patients with clinically significant macular
oedema and proliferative diabetic retinopathy development
between the insulin glargine and NPH insulin groups.
Collectively, these results demonstrate that treatment of
type 2 diabetes mellitus with insulin glargine over 5 years
was not associated with an increase in progression of
diabetic retinopathy, compared with NPH insulin treatment.
Because the primary objective of this study was to
examine effects on diabetic retinopathy, and not to
specifically evaluate intensive glycaemic lowering, similar
levels of glycaemic control were sought by the treatment
strategy, to minimise any confounding effect on the
interpretation of the retinal findings. Despite this intent, a
small difference in HbA1c levels in favour of twice-daily
NPH insulin (7.6% vs 7.8%; p=0.0053) was observed
between the two treatments at endpoint. The statistical
significance was probably detected because of the large
sample size required for the retinopathy primary analysis.
Furthermore, the upper bound of the 95% CI for HbA1c
treatment effect (0.35%) was lower than the non-inferiority
margin of 0.4% commonly used to compare two glucose-
lowering treatments. Given that control of FPG was similar
between the two groups, the lower HbA1c levels in the NPH
insulin arm of the study were presumably due to lower
glucose levels during the day, likely related to the higher
doses of the twice-daily NPH insulin regimen compared
with once-daily insulin glargine, and perhaps to the higher
percentage of patients combining prandial insulin with
NPH insulin. Of note, in the exploratory analysis on the
cohort of approximately one third of the study population
who took basal insulin only, mean HbA1c levels at any visit
were nearly identical in both groups for most of the study.
In any event, the presence of lower HbA1c levels of 0.1% at
baseline and 0.2% at study end in the NPH insulin arm
strengthens the observation that, if different at all, the
retinal changes were slightly less with insulin glargine than
with NPH insulin treatment. Lending further support to this
interpretation is the somewhat greater prevalence of
retinopathy in the insulin glargine group at baseline, both
in terms of medical history and of more severe ETDRS
scores, which might predispose these patients to faster
progression of diabetic retinopathy.
This is the longest controlled study ever reported using
insulin glargine. It has demonstrated sustained glycaemic
improvements and a reduced risk of severe hypoglycaemia
compared with NPH insulin. Furthermore, the average
weight gain was approximately 0.74 and 0.96 kg/year for
insulin glargine and NPH insulin, respectively, over the
5 year study.
The lack of increase in progression of retinopathy seen
with long-term insulin glargine treatment in this study is a
point of discussion in terms of the hypothesis that the
greater binding affinity of insulin glargine compared with
NPH insulin for the IGF-1 receptor may lead to accelerated
progression of retinopathy (a marker of mitogenicity), as
suggested by some in vitro studies [23, 24]. It should be
noted that the majority of in vitro and in vivo studies have
shown that insulin glargine is not associated with increased
mitogenic activity at physiological concentrations [25–28],
and that mitogenicity is only seen in studies using cancer
cell lines and when insulin is administered at supraphysio-
logical concentrations [24, 26]. There is further evidence
against problematic glargine-induced signalling at the
insulin receptor: insulin glargine dissociates rapidly from
the receptor, in contrast to the mitogenic B10Asp insulin,
which dissociates at a much slower rate [29].
The frequency of retinopathy progression observed in
this study was similar to that previously reported in the UK
Prospective Diabetes Study (UKPDS), a large, long-term,
randomised trial of intensive treatment in patients with
newly diagnosed type 2 diabetes mellitus [2, 4]. In a subset
of UKPDS patients with adequate fundus photographs at
both the baseline and 6 year visits (all treatment groups
combined), progression of retinopathy by two or more steps
on the ETDRS scale was observed in 467 of 1,919 patients
(24.3%), which is very similar to the 5 year two or more
step progression observed in our patients (approximately
25%). Caution is required when comparing these frequen-
cies because of differences between the studies, in
particular the side-by-side comparison of baseline and
follow-up photographs used by the Wisconsin grading
centre to confirm progressions of three or more steps,
which may have reduced the frequency observed in our
study. The recently diagnosed type 2 diabetes patients in the
UKPDS and the patients in the present study (mean
diabetes duration 10 years) also differed in terms of the
presence of retinopathy at baseline (defined as at least one
microaneurysm in at least one eye; 37% vs 61%,
respectively).
In summary, this long-term, adequately powered study
robustly confirms that treatment with insulin glargine does
not confer any greater risk of worsening of diabetic
retinopathy than does NPH insulin treatment [18]. More-
over, it provides further new information regarding the
long-term safety of insulin glargine compared with NPH
insulin, beyond that of ophthalmic safety, demonstrating
that similarly sustained improvements in glycaemic control
with a lower risk of hypoglycaemia can be obtained with
once-daily insulin glargine compared with twice-daily NPH
insulin.
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